Apogee Therapeutics (NYSE: APGE) — Perfil da empresa, notícias e dados financeiros
Apogee Therapeutics develops innovative healthcare solutions focused on complex diseases and patient care enhancement.

Apogee Therapeutics
Apogee Therapeutics (NASDAQ:APGE), is at the forefront of developing innovative healthcare solutions aimed at addressing complex diseases. Their operations span from early-stage research to advanced clinical trials, focusing on therapies that promise to transform patient care in areas with unmet medical needs. Apogee Therapeutics is driven by a commitment to science-led breakthroughs, enhancing the quality of life for patients worldwide. Their objectives center around accelerating the delivery of new treatments to the market, forging strategic collaborations to expand their research capabilities, and maintaining a strong ethical stance in all aspects of their operations. Apogee's projects often involve pioneering technologies and novel therapeutic approaches, reflecting the company's dedication to pushing the boundaries of medical science.
Resumo
Operações
Produtos e/ou serviços de Apogee Therapeutics
- Development of innovative immune-modulating therapies for autoimmune diseases.
- Pioneering precision medicine approaches to target specific pathways in immune-mediated disorders.
- Advancement of biologic treatments designed to rebalance the immune system.
- Creation of diagnostic tools for more accurate disease characterization and therapy selection.
- Collaboration with industry and academic partners to accelerate drug discovery and development.
- Investment in cutting-edge research facilities to enhance in-house R&D capabilities for new therapeutic candidates.
equipe executiva do Apogee Therapeutics
- Dr. Michael Thomas Henderson M.D.CEO & Director
- Ms. Jane Pritchett V. HendersonChief Financial Officer
- Dr. Carl Linden Dambkowski M.D.Chief Medical Officer
- Ms. Noel KurdiVice President of Investor Relations
- Mr. Matthew Batters J.D.Chief Legal Officer & Corporate Secretary
- Ms. Emily CoxSVP & Head of People
- Dr. Rebecca Dabora Ph.D.Chief Development Officer
- Ms. Wendy Aspden-CurranSenior Vice President of Clinical Operations
- Dr. Drew Badger Ph.D.Senior VP and Head of Regulatory Affairs & Toxicology
- Ms. Monica ForbesSenior Vice President of Finance
Últimas notícias sobre a Apogee Therapeutics
AbbVie to buys Apogee in $10.9 billion deal
United StatesApogee Therapeutics secures $1.3B Blackstone financing for Phase 3 drug launch
United StatesApogee Therapeutics reports positive Phase 2 eczema trial data
United StatesApogee Therapeutics extends cash runway to 2029 as atopic dermatitis data deepens
United StatesApogee Therapeutics eyes 2026 Phase 3 entry with $902M cash pile
United StatesApogee hits "pipeline-in-a-product" milestone with positive asthma data
United States
Principais indicadores financeiros
Resultados divulgados pela Apogee Therapeutics , em USD.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -285,6 mi | -255,8 mi | |
| 0 | -216,9 mi | -182,1 mi | |
| 0 | -93 mi | -84 mi | |
| 0 | -30,7 mi | -39,8 mi |